Ann: ACW XanaCIDD phase 2a trial topline results, page-127

If a drug reaches the brain it is bioavailable there.

==========

72 of the 185 XanADu patients had blood sample available and biomarker in the AD range.
Of these 72, half were on placebo.
So 36 AD patients were treated.

XanaHES had 42 volunteers with 30 on treatment and 12 on placebo.

So the XanADu reanalysis has slighly more patients on treatment than XanaHES. But the XanaHES results were more significant. One could guess that the dose played a role. But ACW want to follow FDA requirements even outside the USA. FDA says 10mg max.

The subgroup with very elevated biomarker responded better. In a larger sample it would have been statistically significant. This is the only group being selected in the current AD trial.